Evaluation of Prognostic Modification in COVID-19 Patients in Early Intervention Treatment
Status:
Completed
Trial end date:
2021-02-25
Target enrollment:
Participant gender:
Summary
The present study is designed for patients with mild COVID-19 phase, to demonstrate if there
is a modification in the clinical evolution greater than or equal to 25% in their symptoms,
implemented in two groups of patients under an early intervention treatment, a group ( A)
will receive Azithromycin / Ivermectin / Ribaroxaban / Paracetamol and another group (B) will
receive Azithromycin / Ribaroxaban / Paracetamol followed for 14 days followed by video call